Dechert Advises BioAtla in US$72.5 Million Series D Financing
July 17, 2020
Dechert LLP advised BioAtla Inc., a global biotechnology company, in its US$72.5 million Series D financing round. The financing was led by Soleus Capital and included new investors HBM Healthcare Investments as co-lead, as well as Cormorant Asset Management, Farallon Capital, Pappas Capital, funds managed by Janus Henderson, Boxer Capital, and one other institutional investor. Current investor Pfizer Ventures, the venture capital arm of Pfizer Inc., also participated in the financing.
BioAtla focuses on the development of Conditionally Active Biologic (CAB) antibody therapeutics. CABs are proteins generated using BioAtla's proprietary protein discovery, evolution and expression technologies and are used to target cancer cells. The financing will enable the continued design, implementation and execution of clinical programs for the development of tumor-targeting antibodies.
The Dechert team advising BioAtla included life sciences partner David Schulman and associates John Stanley and Carly Robinson (Washington, D.C.), life sciences associate Tiffany Pan (New York) and global tax partner Joshua Milgrim (New York).
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for all clients.
Related Professionals
